<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[226, 228] adverse events<br>[229, 232] personal/logistical reasons.<br>[248, 254] Grade 3-4 haematological toxicities<br>[270, 272] febrile neutropenia<br>[284, 290] liver enzymes and gastrointestinal events;<br>[308, 313] vomiting and throat oedema)<br>[340, 346] Grade 3-4 toxicity.<br></td>
<td width=33%>
[164, 168] proportion of subjects receiving<br>[226, 232] adverse events and personal/logistical reasons.<br>[246, 248] diarrhoea.<br>[248, 252] Grade 3-4<br>[252, 254] haematological toxicities<br>[270, 272] febrile neutropenia<br>[282, 290] increases in liver enzymes and gastrointestinal events;<br>[305, 314] adverse events (vomiting and throat oedema).<br>[340, 346] Grade 3-4 toxicity.<br></td>
<td width=33%>
[18, 22] early breast cancer:<br>[69, 75] dose-dense regimens, but<br>[78, 81] (FEC)<br>[99, 101] toxicity.<br>[164, 175] proportion of subjects receiving > or =85% relative dose intensity<br>[205, 208] were delayed,<br>[216, 219] were delayed.<br>[226, 232] adverse events and personal/logistical reasons.<br>[246, 248] diarrhoea.<br>[248, 252] Grade 3-4<br>[252, 254] haematological toxicities<br>[270, 272] febrile neutropenia<br>[282, 290] increases in liver enzymes and gastrointestinal events;<br>[304, 314] serious adverse events (vomiting and throat oedema).<br>[340, 346] Grade 3-4 toxicity.<br></td>
</tr>
